Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40319-020-00985-0 http://scihub22266oqcxt.onion/10.1007/s40319-020-00985-0 33132411!7592140!33132411     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       IIC+Int+Rev+Ind+Prop+Copyr+Law 2020 ; 51 (9): 1062-1085 Nephropedia Template TP {{tp|p=33132411|t=2020. Strategic Patenting by Pharmaceutical Companies - Should Competition Law Intervene?|pdf=|usr=}}{{33132411}} gab.com Text Strategic Patenting by Pharmaceutical Companies - Should Competition Law Intervene JO: IIC Int Rev Ind Prop Copyr Law http://www.kidney.de/pget.php?&tw=1&pmid=33132411 #FOAvip As the COVID-19 pandemic is affecting the lives of thousands of people worldwide, the problem of timely access to affordable medicines has intensified today. Based on past experience of accessing medicines for life-threatening diseases there is a justifiable fear that access to any vaccines and treatments that are eventually developed may be hindered by patents, leading to unaffordable prices. In particular, one of the reasons that typically leads to high prices is strategic patenting employed by pharmaceutical companies. While this practice is currently considered lawful, this article argues that strategic patenting requires a long-overdue intervention by competition authorities and aims to attract their attention to its harmful effects. It maintains that, along with a more immediate negative effect in the form of high drug prices, strategic patenting affects dynamic competition by stifling innovation of both originators and generic companies. The article outlines the current approach to strategic patenting and provides arguments for the intervention of competition law. This, in turn, will open the possibility for competition authorities to investigate this practice and prevent its harmful effect on drug prices and pharmaceutical innovation, for the benefit of consumer welfare. Twit Text FOAVip Strategic Patenting by Pharmaceutical Companies - Should Competition Law Intervene ????IIC Int Rev Ind Prop Copyr Law http://www.kidney.de/pget.php?&tw=1&pmid=33132411 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33132411 #FOAvip English Wikipedia <ref>{{Cite pmid|33132411}}</ref> Strategic Patenting by Pharmaceutical Companies - Should Competition Law Intervene? #MMPMID33132411 Gurgula O IIC Int Rev Ind Prop Copyr Law 2020[]; 51 (9): 1062-1085 PMID33132411show ga As the COVID-19 pandemic is affecting the lives of thousands of people worldwide, the problem of timely access to affordable medicines has intensified today. Based on past experience of accessing medicines for life-threatening diseases there is a justifiable fear that access to any vaccines and treatments that are eventually developed may be hindered by patents, leading to unaffordable prices. In particular, one of the reasons that typically leads to high prices is strategic patenting employed by pharmaceutical companies. While this practice is currently considered lawful, this article argues that strategic patenting requires a long-overdue intervention by competition authorities and aims to attract their attention to its harmful effects. It maintains that, along with a more immediate negative effect in the form of high drug prices, strategic patenting affects dynamic competition by stifling innovation of both originators and generic companies. The article outlines the current approach to strategic patenting and provides arguments for the intervention of competition law. This, in turn, will open the possibility for competition authorities to investigate this practice and prevent its harmful effect on drug prices and pharmaceutical innovation, for the benefit of consumer welfare. äStrategic Patenting by Pharmaceutical Companies - Should Competition L(epmc).pdf DeepDyve Pubget Overpricing